Skip to content

Non-invasive Evaluation of Portal Pressure by MRI

Using MRI for a Non-invasive Evaluation of Portal Pressure

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02530567
Acronym
ENIP
Enrollment
100
Registered
2015-08-21
Start date
2015-10-31
Completion date
2019-07-31
Last updated
2019-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Disease

Keywords

portal pressure, portosystemic pressure gradient, azygos blood flow

Brief summary

The objective of this research is to study the correlation between the portosystemic pressure gradient and azygos blood flow measured by MRI.

Detailed description

All patients will benefit from: * Pressure gradient measurement portosystemic * MRI measurement of azygos flow, aortic, portals, spleen and lower cellar * Liver biopsy * Laboratory tests

Interventions

PROCEDUREIntervention

All patients performing the biopsy will have an MRI to carry out the necessary measures.

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Suspicion of chronic liver disease * Indication to perform a liver biopsy transjugular * Patient able to consent

Exclusion criteria

* contraindication to MRI: * Holders of a pacemaker or a defibrillator, an implanted material activated by electrical, magnetic or mechanical * Holders of hemostatic clips intracerebral aneurysms or carotid arteries, bearing orthopedic implants * claustrophobic * Severe hepatic encephalopathy * Inability to MRI in the week surrounding the first jugular

Design outcomes

Primary

MeasureTime frameDescription
Correlation between portosystemic pressure gradient measured by catheterization of the hepatic veins transjugular and azygos flow measured by MRI.1 weekMRI and catheterization will be performed the same week. For the azygos blood flow (by MRI), measures will be repeated 5 times. Speed of extraction and the rate on the post processing console will be made with a double reading. For the measurement of portal pressure by catheterization, will be performed measurements of occluded hepatic vein pressure and free hepatic vein. They will be repeated 3 times each. These measures will be carried out to calculate the portosystemic pressure gradient. The flow rate and gradient measurements will be performed blindly to the other.

Secondary

MeasureTime frameDescription
Correlation between portosystemic pressure gradient measured by catheterization of the hepatic veins transjugular and aortic flow measured by MRI.1 weekThis outcome is different of primary outcome because the Measurement of azygos blood flow (MRI) is repeated on a strictly perpendicular section to the vessel facing the T4-T5 disk and the extraction speed rate and on post processing console is made by double reading. Measuring portal pressure by catheterization. Measurements of occluded hepatic vein pressure and free hepatic vein and will be repeated 3 times each. Flow measurements and gradient will be carried out blind to each other by the radiologist and the hepatologist.
Correlation between portosystemic pressure gradient measured by catheterization of the hepatic veins transjugular and throughput inferior vena measured by MRI.1 weekMeasurement of azygos blood flow (MRI) Repeated Measure 5 times on a strictly perpendicular cut to the vessel immediately after anastomosis of the hepatic veins to the inferior vena cava and Extraction speed and flow on post processing console with double reading. Measurement of portal pressure by catheterization It will be defined by the measures of occluded hepatic vein pressure and free hepatic vein and measurements will be repeated 3 times each. The flow rate and gradient measurements will be performed blindly to the other.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026